<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112502</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0662</org_study_id>
    <secondary_id>MDA-ID-02586</secondary_id>
    <secondary_id>NCI-6636</secondary_id>
    <secondary_id>MDA-2004-0662</secondary_id>
    <secondary_id>CDR0000432954</secondary_id>
    <secondary_id>NCI-2009-00076</secondary_id>
    <nct_id>NCT00112502</nct_id>
  </id_info>
  <brief_title>Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme</brief_title>
  <official_title>A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Thalidomide may stop the growth of glioblastoma multiforme by blocking blood flow to the&#xD;
      tumor. Isotretinoin may help cells that are involved in the body's immune response to work&#xD;
      better. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. It is not yet known which temozolomide-containing regimen is more effective&#xD;
      in treating glioblastoma multiforme.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying eight different temozolomide-containing&#xD;
      regimens to compare how well they work in treating patients who have undergone radiation&#xD;
      therapy for glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of adjuvant temozolomide (TMZ) alone or in combination with&#xD;
           thalidomide and/or isotretinoin and/or celecoxib, in terms of 6-month progression-free&#xD;
           survival, in patients who have undergone radiotherapy for supratentorial glioblastoma&#xD;
           multiforme.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 8 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral temozolomide once daily on days 1-7 and 15-21.&#xD;
&#xD;
        -  Arm II: Patients receive temozolomide as in arm I and oral thalidomide once daily on&#xD;
           days 1-28.&#xD;
&#xD;
        -  Arm III: Patients receive temozolomide as in arm I and oral isotretinoin twice daily on&#xD;
           days 1-21.&#xD;
&#xD;
        -  Arm IV: Patients receive temozolomide as in arm I and oral celecoxib twice daily on days&#xD;
           1-28.&#xD;
&#xD;
        -  Arm V: Patients receive temozolomide as in arm I, thalidomide as in arm II, and&#xD;
           isotretinoin as in arm III.&#xD;
&#xD;
        -  Arm VI: Patients receive temozolomide as in arm I, thalidomide as in arm II, and&#xD;
           celecoxib as in arm IV.&#xD;
&#xD;
        -  Arm VII: Patients receive temozolomide as in arm I, isotretinoin as in arm III, and&#xD;
           celecoxib as in arm IV.&#xD;
&#xD;
        -  Arm VIII: Patients receive temozolomide as in arm I, thalidomide as in arm II,&#xD;
           isotretinoin as in arm III, and celecoxib as in arm IV.&#xD;
&#xD;
      In all arms, treatment repeats every 28 days for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patient may receive additional courses of therapy at&#xD;
      the discretion of the treating physician.&#xD;
&#xD;
      After completion of study treatment, patients are followed for at least 30 days and then&#xD;
      every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms</measure>
    <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).</time_frame>
    <description>Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Progression-Free Survival (PFS) Comparison of Celecoxib Arms Versus no Celecoxib Arms</measure>
    <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Progression-Free Survival (PFS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms</measure>
    <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival (PFS) Comparison of Doublet Versus Triplet Therapy</measure>
    <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival (PFS) of Individual Arms</measure>
    <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) Comparison of Thalidomide Arms Versus no Thalidomide Arms</measure>
    <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) Comparison of Celecoxib Arms Versus no Celecoxib Arms</measure>
    <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms</measure>
    <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS) Comparison of Doublet Versus Triplet Therapy</measure>
    <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival of Individual Arms</measure>
    <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
    <description>Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Arm I: TMZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: TMZ + Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III: TMZ + Isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV: TMZ + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400 mg orally twice a day continuous dosing</description>
    <arm_group_label>Arm IV: TMZ + Celecoxib</arm_group_label>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
    <arm_group_label>Arm III: TMZ + Isotretinoin</arm_group_label>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>13-Cis-Retinoic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>150 mg/m2 orally daily, 7 days on treatment, 7 days off.</description>
    <arm_group_label>Arm I: TMZ</arm_group_label>
    <arm_group_label>Arm II: TMZ + Thalidomide</arm_group_label>
    <arm_group_label>Arm III: TMZ + Isotretinoin</arm_group_label>
    <arm_group_label>Arm IV: TMZ + Celecoxib</arm_group_label>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_label>Arm VII: TMZ + Isotretinoin + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)</description>
    <arm_group_label>Arm II: TMZ + Thalidomide</arm_group_label>
    <arm_group_label>Arm V: TMZ + Thalidomide + Isotretinoin</arm_group_label>
    <arm_group_label>Arm VI: TMZ + Thalidomide + Celecoxib</arm_group_label>
    <arm_group_label>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial glioblastoma multiforme&#xD;
&#xD;
          -  Must have undergone a biopsy OR subtotal or gross total resection of the tumor&#xD;
&#xD;
          -  Must have completed post-operative (or post-biopsy) radiotherapy within the past 5&#xD;
             weeks&#xD;
&#xD;
               -  No progressive disease after radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  blood urea nitrogen (BUN) ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to celecoxib or to sulfonamides&#xD;
&#xD;
          -  No asthma, urticaria, or allergic reactions to aspirin or other NSAIDs&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
          -  No gastrointestinal bleeding within past 3 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception during and for 2&#xD;
             months after study participation&#xD;
&#xD;
               -  Fertile female patients randomized to receive thalidomide must use effective&#xD;
                  double-method contraception for ≥ 4 weeks before, during, and ≥ 4 weeks after&#xD;
                  completion of study therapy&#xD;
&#xD;
               -  Fertile male patients randomized to receive thalidomide must use effective&#xD;
                  contraception during and for ≥ 4 weeks after completion of study therapy&#xD;
&#xD;
          -  No blood donation (for patients randomized to receive thalidomide)&#xD;
&#xD;
          -  No history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of&#xD;
             the cervix or cancer that is in complete remission and patient completed all therapy&#xD;
             for that disease ≥ 3 years ago&#xD;
&#xD;
          -  No other disease that would obscure toxicity or dangerously alter drug metabolism&#xD;
             (e.g., severe connective tissue disease)&#xD;
&#xD;
          -  No other serious medical illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior temozolomide in combination with radiotherapy allowed&#xD;
&#xD;
          -  No other prior or concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent non-steroidal anti-inflammatory drugs (NSAIDs) (for patients&#xD;
             randomized to receive celecoxib)&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Penas-Prado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hembree Mercy Cancer Center at St. Edward Mercy Medical Center</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-2134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Atlanta Regional</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas (UT) MD Anderson Cancer Center Official Website</description>
  </link>
  <results_reference>
    <citation>Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010 Nov;12(11):1167-72. doi: 10.1093/neuonc/noq100. Epub 2010 Aug 20.</citation>
    <PMID>20729242</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 2005 to February 2011 from various hospitals and institutions representing the Community Clinical Oncology Program (CCOP). A total of 146 participants were accrued at MD Anderson Cancer Center and 32 at the remaining participating sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I: TMZ</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
        </group>
        <group group_id="P2">
          <title>Arm II: TMZ + Thalidomide</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="P3">
          <title>Arm III: TMZ + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
        </group>
        <group group_id="P4">
          <title>Arm IV: TMZ + Isotretinoin</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="P5">
          <title>Arm V: TMZ + Isotretinoin + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="P6">
          <title>Arm VI: TMZ + Thalidomide + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="P7">
          <title>Arm VII: TMZ + Thalidomide + Isotretinoin</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="P8">
          <title>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A 178 participants in total were randomized, out of which 23 participants were randomized but not treated because of consent withdrawal with some further difficulties obtaining insurance coverage.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I: TMZ</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
        </group>
        <group group_id="B2">
          <title>Arm II: TMZ + Thalidomide</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="B3">
          <title>Arm III: TMZ + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
        </group>
        <group group_id="B4">
          <title>Arm IV: TMZ + Isotretinoin</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="B5">
          <title>Arm V: TMZ + Isotretinoin + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="B6">
          <title>Arm VI: TMZ + Thalidomide + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="B7">
          <title>Arm VII: TMZ + Thalidomide + Isotretinoin</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="B8">
          <title>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="23"/>
            <count group_id="B6" value="22"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="22"/>
            <count group_id="B9" value="178"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=19 years:</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 20 and 59 years:</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60 years:</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms</title>
        <description>Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII</title>
            <description>Arm II: TMZ + Thalidomide, Arm VI: TMZ + Thalidomide + Celecoxib, Arm VII: TMZ + Thalidomide + Isotretinoin and Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>No Thalidomide: Arm I, Arm III, Arm IV and Arm V</title>
            <description>Arm I: TMZ, Arm III: TMZ + Celecoxib, Arm IV: TMZ + Isotretinoin and Arm V: TMZ + Isotretinoin + Celecoxib&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms</title>
          <description>Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="8.7" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Progression-Free Survival (PFS) Comparison of Celecoxib Arms Versus no Celecoxib Arms</title>
        <description>Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib: Arm III, Arm V, Arm VI and Arm VIII</title>
            <description>Arm III: TMZ + Celecoxib, Arm V: TMZ + Isotretinoin + Celecoxib, Arm VI: TMZ + Thalidomide + Celecoxib and Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>No Celecoxib: Arm I, Arm II, Arm IV and Arm VII</title>
            <description>Arm I: TMZ, Arm II: TMZ + Thalidomide, Arm IV: TMZ + Isotretinoin and Arm VII: TMZ + Thalidomide + Isotretinoin.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (PFS) Comparison of Celecoxib Arms Versus no Celecoxib Arms</title>
          <description>Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="7.4" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Progression-Free Survival (PFS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms</title>
        <description>Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isotretinoin: Arm IV, Arm V, Arm VII and Arm VIII</title>
            <description>Arm IV: TMZ + Isotretinoin, Arm V: TMZ + Isotretinoin + Celecoxib, Arm VII: TMZ + Thalidomide + Isotretinoin and Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>No Isotretinoin: Arm I, Arm II, Arm III and Arm VI</title>
            <description>Arm I: TMZ, Arm II: TMZ + Thalidomide, Arm III: TMZ + Celecoxib and Arm VI: TMZ + Thalidomide + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (PFS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms</title>
          <description>Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="9.1" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-Free Survival (PFS) Comparison of Doublet Versus Triplet Therapy</title>
        <description>Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doublet (2 Agents): Arm II, Arm III and Arm IV</title>
            <description>Arm II: TMZ + Thalidomide, Arm III: TMZ + Celecoxib and Arm IV: TMZ + Isotretinoin&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Triplet (3 Agents): Arm V, Arm VI and Arm VII</title>
            <description>Arm V: TMZ + Isotretinoin + Celecoxib, Arm VI: TMZ + Thalidomide + Celecoxib and Arm VII: Thalidomide + Celecoxib + Isotretinoin&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (PFS) Comparison of Doublet Versus Triplet Therapy</title>
          <description>Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="8.2" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-Free Survival (PFS) of Individual Arms</title>
        <description>Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I: TMZ</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: TMZ + Thalidomide</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
          <group group_id="O3">
            <title>Arm III: TMZ + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV: TMZ + Isotretinoin</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O5">
            <title>Arm V: TMZ + Isotretinoin + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O6">
            <title>Arm VI: TMZ + Thalidomide + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
          <group group_id="O7">
            <title>Arm VII: TMZ + Thalidomide + Isotretinoin</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
          <group group_id="O8">
            <title>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival (PFS) of Individual Arms</title>
          <description>Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="7.7" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O3" value="13.4" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O4" value="6.5" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O5" value="11.6" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O6" value="7.9" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O7" value="6.2" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O8" value="5.8" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) Comparison of Thalidomide Arms Versus no Thalidomide Arms</title>
        <description>Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII</title>
            <description>Arm II: TMZ + Thalidomide, Arm VI: TMZ + Thalidomide + Celecoxib, Arm VII: TMZ + Thalidomide + Isotretinoin and Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>No Thalidomide: Arm I, Arm III, Arm IV and Arm V</title>
            <description>Arm I: TMZ, Arm III: TMZ + Celecoxib, Arm IV: TMZ + Isotretinoin and Arm V: TMZ + Isotretinoin + Celecoxib&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS) Comparison of Thalidomide Arms Versus no Thalidomide Arms</title>
          <description>Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="17.4" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) Comparison of Celecoxib Arms Versus no Celecoxib Arms</title>
        <description>Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib: Arm III, Arm V, Arm VI and Arm VIII</title>
            <description>Arm III: TMZ + Celecoxib, Arm V: TMZ + Isotretinoin + Celecoxib, Arm VI: TMZ + Thalidomide + Celecoxib and Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>No Celecoxib: Arm I, Arm II, Arm IV and Arm VII</title>
            <description>Arm I: TMZ, Arm II: TMZ + Thalidomide, Arm IV: TMZ + Isotretinoin and Arm VII: TMZ + Thalidomide + Isotretinoin.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS) Comparison of Celecoxib Arms Versus no Celecoxib Arms</title>
          <description>Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="17.1" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms</title>
        <description>Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isotretinoin: Arm IV, Arm V, Arm VII and ARM VIII</title>
            <description>Arm IV: TMZ + Isotretinoin, Arm V: TMZ + Isotretinoin + Celecoxib, Arm VII: TMZ + Thalidomide + Isotretinoin and Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>No Isotretinoin: Arm I, Arm II, Arm III and ARM VI</title>
            <description>Arm I: TMZ, Arm II: TMZ + Thalidomide, Arm III: TMZ + Celecoxib and Arm VI: TMZ + Thalidomide + Celecoxib&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms</title>
          <description>Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="19.9" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS) Comparison of Doublet Versus Triplet Therapy</title>
        <description>Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doublet (2 Agents): Arm II, Arm III and Arm IV</title>
            <description>Arm II: TMZ + Thalidomide, Arm III: TMZ + Celecoxib and Arm IV: TMZ + Isotretinoin&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Triplet (3 Agents): Arm V, Arm VI and Arm VII</title>
            <description>Arm V: TMZ + Isotretinoin + Celecoxib, Arm VI: TMZ + Thalidomide + Celecoxib and Arm VII: Thalidomide + Celecoxib + Isotretinoin&#xD;
Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS) Comparison of Doublet Versus Triplet Therapy</title>
          <description>Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="20.1" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival of Individual Arms</title>
        <description>Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Every 3 months from randomization until progression of disease, death or last follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I: TMZ</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: TMZ + Thalidomide</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
          <group group_id="O3">
            <title>Arm III: TMZ + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV: TMZ + Isotretinoin</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O5">
            <title>Arm V: TMZ + Isotretinoin + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
          </group>
          <group group_id="O6">
            <title>Arm VI: TMZ + Thalidomide + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
          <group group_id="O7">
            <title>Arm VII: TMZ + Thalidomide + Isotretinoin</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
          <group group_id="O8">
            <title>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</title>
            <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival of Individual Arms</title>
          <description>Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O2" value="17.4" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O3" value="18.1" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O4" value="11.7" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O5" value="23.1" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O6" value="20.2" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O7" value="17.9" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                    <measurement group_id="O8" value="18.5" lower_limit="NA" upper_limit="NA">95% Confidence Interval values are not available to be reported as the PI has left the institution and no study team member is present. Sincere efforts were made to obtain the data for reporting, but were unsuccessful</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) and Serious Adverse Events (SAEs) were collected from study drug administration to time of progression, death, or last follow-up,1 year&quot;, &quot;Adverse Events (AEs) and Serious Adverse Events (SAEs) were collected from study drug administration to time of progression, death, or last follow-up, up to 5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I: TMZ</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.</description>
        </group>
        <group group_id="E2">
          <title>Arm II: TMZ + Thalidomide</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="E3">
          <title>Arm III: TMZ + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.</description>
        </group>
        <group group_id="E4">
          <title>Arm IV: TMZ + Isotretinoin</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="E5">
          <title>Arm V: TMZ + Isotretinoin + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.</description>
        </group>
        <group group_id="E6">
          <title>Arm VI: TMZ + Thalidomide + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="E7">
          <title>Arm VII: TMZ + Thalidomide + Isotretinoin</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
        <group group_id="E8">
          <title>Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib</title>
          <description>Oral Temozolomide (TMZ): 150 mg/m^2 once daily on days 1-7 and 15-21.&#xD;
Celecoxib: 400 mg orally twice a day continuous dosing.&#xD;
Isotretinoin: 40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.&#xD;
Thalidomide: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gait/Walking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pyramidal Tract Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="54" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E2" events="28" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" events="43" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E4" events="34" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E5" events="66" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E6" events="35" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E7" events="36" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E8" events="32" subjects_affected="14" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="99" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" events="35" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E3" events="70" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E4" events="50" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E5" events="74" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E6" events="69" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E7" events="23" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E8" events="17" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="37" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E2" events="25" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E3" events="30" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="21" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E5" events="19" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E6" events="24" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E7" events="27" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E8" events="22" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="35" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="28" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E4" events="17" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E5" events="31" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E6" events="26" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E7" events="22" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" events="14" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="39" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" events="39" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" events="31" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E5" events="39" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E6" events="45" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E7" events="25" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" events="26" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hematocrit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CO2 Serum High</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Limb</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>High Lactate Dehydrogenase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>High BUN Serum</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Head and Neck</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thrombotic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low BUN Serum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bilateral Ankle Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Lactate Dehydrogenase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia-Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia-Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Left Ear Drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ear Wax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tympanic Membrane Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Testosterone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thyroid Problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anopsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lowered Visual Acuity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Loss of Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Watery Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eyelid Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Extraocular Movement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Exophoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Esotropia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Conjunctival Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Asymmetrical Optic Cup</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anisocoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Swollen Eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E6" events="14" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E6" events="13" subjects_affected="10" subjects_at_risk="17"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdomen/GI Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mouth Sores</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Periodontal Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Intermittent Appetite Change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anal Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E5" events="20" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E6" events="26" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E7" events="16" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E8" events="16" subjects_affected="14" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Extremity-limb</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Absence of Neutropenia</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flu-Like Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" events="9" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gilbert's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Allergy</sub_title>
                <description>Penicillin</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Allergy</sub_title>
                <description>Iodine</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Normal ANC or Grade 1 or 2 neutrophils</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Opportunistic Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infection with Unknown ANC</sub_title>
                <description>Vagina - yeast</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC</sub_title>
                <description>Eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC</sub_title>
                <description>Abdomen/GI</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Toe Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC</sub_title>
                <description>Prostate</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="18" subjects_at_risk="22"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" events="38" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" events="20" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E5" events="17" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E6" events="18" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E7" events="20" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="15" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" events="21" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E5" events="30" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="17" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E8" events="14" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E5" events="23" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="17" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E5" events="22" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="11" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Bicarbonate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>High Chloride Serum</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>High Bicarbonate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Chloride Serum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Protein Serum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>High Protein Serum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Uric Acid</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperalbuminenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatine Phosphokinase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E6" events="14" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gait/Walking</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Involuntary Movement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Unsteady Gait</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ankle Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Jaw Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Wrist Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hip Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bilateral Hands/Feet Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscles Twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Deep Tendon Reflexes - Limb</sub_title>
                <description>Decreased/Increased</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Left Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Polyp in the Cardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hepatic Hemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cervical Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Asymptomatic Thyroid Nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E5" events="17" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E7" events="16" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E6" events="13" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyramidal Tract Dysfunction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>Cranial</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy - Motor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy - Sensory</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysesthesias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="14" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E6" events="12" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Phenytoin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mood Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CN VI Palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Short Term Memory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dystonic Meige Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Left VII CN Palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Light Headedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Facial Droop</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Suprapubic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Membranous Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stress Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bladder Spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Burning During Urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Irregular Menses</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Orgasmic dyfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vaginal Dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paranasal Sinus Reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vital Capacity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Voice Changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Throat Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Larynx</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CO2 Serum Low</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" events="12" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E5" events="19" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" events="10" subjects_affected="10" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Facial Hair Growth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cheilosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ecchymosis Lower Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Uticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <description>Face and Right Ear</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <description>Non-Infectious</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin Sensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Agraphesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Varicosities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <description>Colon/Cecum/Appendix</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vein Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John F de Groot, Chair Ad Interim, Neuro-Oncology</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-745-3072</phone>
      <email>jdegroot@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

